Tryton Medical Inc. closed a $20 million Series D financing round.
The Durham, N.C.-based company said it plans to use the cash to fund a pivotal trial of its bifurcation lesion-treating stent in the U.S. and for its international marketing operation.
The balloon-expandable cobalt chromium-based "side branch stent" is designed to treat bifurcated lesions in cardiac arteries, according to a press release.
Private healthcare investor Arnerich Massena led the round and added Russell Rottiers to the Tryton board. Previous investors PTV Sciences, RiverVest Venture Partners and Spray Venture Partners also participated.
Tryton operated in Newton, Mass. from the company’s founding in 2003 through 2008, when it began the move (PDF) to Research Triangle Park in the Tar Heel State.
The company’s C round brought in $14 million in venture financing from PTV Sciences and RiverVest Venture Partners in March 2008. At the time, Tryton said the funding would help it advance both European commercialization and clinical trials in the U.S. The company won CE Mark approval (PDF) for the stent about two months before that round closed.
In May, the company announced positive data for its stent system at the EuroPCR 2010 conference in Paris.